NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC
-Two human phase II clinical trials to be conducted in 2021
-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis
-The second trial will focus on ETEC infections
finance.yahoo.com/news/us-dod-naval-medical-research-100010355.html
-Two human phase II clinical trials to be conducted in 2021
-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis
-The second trial will focus on ETEC infections
finance.yahoo.com/news/us-dod-naval-medical-research-100010355.html
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。